Publications by authors named "Glynn Jones"
Background: Parkinson's disease is a progressive neurodegenerative disease, which significantly impacts patients' quality of life and is associated with high treatment and direct healthcare costs. In England, levodopa/carbidopa intestinal gel (LCIG) is indicated for the treatment of levodopa-responsive advanced Parkinson's disease with troublesome motor fluctuations when available combinations of medicinal products are unsatisfactory.
Objective: We aimed to determine the cost effectiveness of LCIG compared to the standard of care for patients with advanced Parkinson's disease in England, using real-world data.
Post-mortem investigations of human Alzheimer's disease (AD) have largely failed to provide unequivocal evidence in support of the original amyloid cascade hypothesis, which postulated deposition of β-amyloid (Aβ) aggregates to be the cause of a demented state as well as inductive to tau neurofibrillary tangles (NFTs). Conflicting evidence suggests, however, that Aβ plaques and NFTs, albeit to a lesser extent, are present in a substantial subset of non-demented individuals. Hence, a range of soluble tau and Aβ species has more recently been implicated as the disease-relevant toxic entities.
View Article and Find Full Text PDFAim: To develop a non-invasive management strategy for men with lower urinary tract symptoms (LUTS) after treatment for pelvic cancer, that is suitable for use in a primary healthcare context.
Methods: PubMed literature searches of LUTS management in this patient group were carried out, together with obtaining a consensus of management strategies from a panel of authors for the management of LUTS from across the UK.
Results: Data from 41 articles were investigated and collated.
Article Synopsis
- Scientists created a special medicine called RI-OR2-TAT that helps stop the harmful proteins linked to Alzheimer's disease from forming in the brain.
- Tests showed that this medicine could cross into the brain tissue and attach to bad proteins and cells that are involved in causing memory loss.
- After giving this medicine to mice for 21 days, they found significant improvements, like fewer harmful proteins and more new brain cells, suggesting it could help treat Alzheimer's in people in the future.